Our model integrates basic viral dynamics from the OV43,44 and the immune pressure on the cancer cells while also including pharmacokinetic (PK) models for TRAIL and PAC-1 and their combined pharmacodynamics (PDs).45,46 After model parameterization to in vitro data, we explored the effects of increasing tumor size and the immune response to combination therapy. The gene discussed is TNFSF10; the disease is cancer.